A new six-month treatment reg­i­men to treat druf-resistant tuberculosis marks a potentially transformative shift.

RE104 is a proprietary, potential best-in-class, patented prodrug of 4-OH-DiPT, which is administered via a single subcutaneous injection. Reunion designed RE104 to deliver a short, acute psychoactive ...

A high-level stakeholder consultation meeting was held on Tuesday on deploying the “advanced, short-term BPaL/M treatment ...

Some survivors of tuberculosis (TB) have urged those living with the condition to make taking their medication their optimum goal if they want to stay alive ...

E-commerce giant Amazon has now confirmed that 10 employees at its Coventry, UK warehouse contracted tuberculosis (TB) in ...

Tony Cholerton created Robovacc to inoculate a timid tiger at London zoo – but says it could administer jabs to badgers ...

We talked to experts in obesity, tobacco, artificial intelligence, HIV, TB and the NHI to find out what we can expect – and ...

A new underground industry has emerged where people are buying raw compounds for Ozempic, Botox, filler and skin-tightening ...

UCB Canada Inc. is pleased to announce Health Canada has granted a Notice of Compliance (NOC) for PrBIMZELX® (bimekizumab injection) indicated for the treatment ...

Aligned with U.S. Food and Drug Administration (FDA) on Registrational Path for RE104 in Postpartum Depression (PPD); On Track to Initiate ...

You know the drill by now. You're sitting in the purgatory of the service center waiting room. Precisely 63 minutes into your wait, the service adviser walks out with a clipboard and calls your name — ...